Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.26 USD | -7.39% | -11.45% | -6.90% |
Financials (USD)
Sales 2024 * | 6.18M | Sales 2025 * | 5.93M | Capitalization | 265M |
---|---|---|---|---|---|
Net income 2024 * | -143M | Net income 2025 * | -171M | EV / Sales 2024 * | 23.2 x |
Net cash position 2024 * | 122M | Net cash position 2025 * | 171M | EV / Sales 2025 * | 15.7 x |
P/E ratio 2024 * |
-2.28
x | P/E ratio 2025 * |
-2.27
x | Employees | 133 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.11% |
Latest transcript on Monte Rosa Therapeutics, Inc.
1 day | -7.39% | ||
1 week | -11.45% | ||
Current month | -1.13% | ||
1 month | -29.96% | ||
3 months | +12.15% | ||
6 months | +42.55% | ||
Current year | -6.90% |
Managers | Title | Age | Since |
---|---|---|---|
Markus Warmuth
CEO | Chief Executive Officer | 53 | 19-12-31 |
Chief Operating Officer | - | 21-02-28 | |
Filip Janku
CTO | Chief Tech/Sci/R&D Officer | 50 | 21-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Schiff
CHM | Chairman | 58 | 20-08-31 |
Christine Siu
BRD | Director/Board Member | 47 | 20-11-30 |
Chandra Paul Leo
BRD | Director/Board Member | 53 | 20-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.00% | 0 M€ | +8.23% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 5.26 | -7.39% | 137,485 |
24-05-07 | 5.68 | -1.39% | 189,931 |
24-05-06 | 5.76 | +1.95% | 54,036 |
24-05-03 | 5.65 | +0.89% | 80,628 |
24-05-02 | 5.6 | -5.72% | 176,103 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.90% | 265M | |
+22.56% | 46.71B | |
-1.51% | 41.52B | |
+48.83% | 41.8B | |
-3.42% | 29.55B | |
+10.13% | 25.78B | |
-20.44% | 19.26B | |
+26.45% | 11.98B | |
-0.14% | 12.14B | |
-0.47% | 12.08B |
- Stock Market
- Equities
- GLUE Stock